Related references
Note: Only part of the references are listed.Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study
Nemanja Vaci et al.
BRITISH JOURNAL OF PSYCHIATRY (2021)
The Clinician's Interview-Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response
Justin Stanley et al.
ALZHEIMERS & DEMENTIA (2021)
SciPy 1.0: fundamental algorithms for scientific computing in Python
Pauli Virtanen et al.
NATURE METHODS (2020)
Natural language processing for structuring clinical text data on depression using UK-CRIS
Nemanja Vaci et al.
EVIDENCE-BASED MENTAL HEALTH (2020)
Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate 'Real World' Evidence of Comparative Effectiveness and Safety
Shirley V. Wang et al.
DRUG SAFETY (2019)
The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review
Jacqueline K. Kueper et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Donepezil for dementia due to Alzheimer's disease
Jacqueline S. Birks et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
Update on SSRI Treatment for Neuropsychiatric Symptoms of Dementia
James M. Wilkins et al.
CURRENT PSYCHIATRY REPORTS (2016)
Predictive Factors of Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer's Disease and Mixed Dementia: A One-Year Naturalistic Study
Luis F. J. R. Miranda et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
Anton P. Porsteinsson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Role of citalopram in the treatment of agitation in Alzheimer's disease
Anton P. Porsteinsson et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2014)
Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging
David R. Roalf et al.
ALZHEIMERS & DEMENTIA (2013)
Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome
Benjamin Lam et al.
ALZHEIMERS RESEARCH & THERAPY (2013)
Assessment scales in dementia
Bart Sheehan
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2012)
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial
Sube Banerjee et al.
LANCET (2011)
Antidepressants for agitation and psychosis in dementia
D. P. Seitz et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2011)
Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease
Alberto Pilotto et al.
NEUROLOGY (2009)
Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease
R Bullock et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice
MH Trivedi et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Diagnosis and treatment of depression in Alzheimer's disease - A practical update for the clinician
CG Lyketsos et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2004)
A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil
SI Finkel et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2004)
Qualitative analysis of the Clinician Interview-Based Impression of Change (Plus): Methodological issues and implications for clinical research
C Joffres et al.
INTERNATIONAL PSYCHOGERIATRICS (2000)